Unither | United Therapeutics Corporation

Board of Directors

Christopher Causey, M.B.A.

  • Principal, Causey Consortium
  • Independent Director
  • Chairman, Compensation Committee
  • Member, Nominating and Governance Committee
Christopher Causey, M.B.A.

Mr. Causey has served as the Principal of the Causey Consortium, a professional services organization providing business strategy and marketing counsel to the healthcare industry, since 2002. Previously, Mr. Causey served as a senior marketing officer for a variety of healthcare and technology companies. From 2001 to 2002, Mr. Causey served as the Chief Marketing Officer for Definity Health Incorporated. From 2008 to 2013, he served as a member of the Board of Directors of Data Sciences International, Inc., a private company that develops wireless physiological monitoring solutions. Mr. Causey has served as a United Therapeutics director since 2003.

Prof. Raymond Dwek, F.R.S.

  • Professor of Glycobiology
  • Director of the Glycobiology Institute
  • University of Oxford
  • Non-employee Director
  • Chairman, Scientific Committee
Prof. Raymond Dwek, F.R.S.

Professor Dwek is a Fellow of the Royal Society, London, and has served as Director of the Glycobiology Institute and Professor of Glycobiology at the University of Oxford since 1988. He was President of the Institute of Biology (a professional organization) from 2008 through 2010. From 2000 to 2006, Professor Dwek served as head of the Department of Biochemistry at the University of Oxford. Professor Dwek has been serving in various positions at the University of Oxford since 1966. In 1988, Professor Dwek was the scientific founder of Oxford GlycoSciences PLC, which was publicly traded on the London Stock Exchange and NASDAQ, and he served as a member of its Board of Directors until its sale in 2003. He was the 2007 Kluge Chair of Technology and Society at the U.S. Library of Congress. Professor Dwek is the founder of glycobiology, the study of the structure, biosynthesis and biology of sugar chains attached to proteins. He has served as a United Therapeutics director since 2002.

Richard Giltner

  • Private Investor
  • Former Managing Director, Société Générale Asset Management
  • Independent Director
  • Member, Audit Committee
  • Member, Nominating and Governance Committee
Richard Giltner

From 2009 until 2010, Mr. Giltner was a portfolio manager at Lyxor Asset Management, an asset management group at the French bank Société Générale. From 2006 until 2009, he served as a managing director of Société Générale Asset Management, an international fund management firm, and head of the European office for its fund of hedge funds group. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Société Générale. He also held various other managerial positions within Société Générale from 1991 until 2003. Mr. Giltner has been a private investor since his retirement from Société Générale in 2010. Our Board of Directors has determined that Mr. Giltner meets the financial sophistication requirements of NASDAQ’s listing standards. Mr. Giltner has served as a United Therapeutics director since 2009.

Ray Kurzweil

  • Director of Engineering, Google, Inc.
  • Founder, Chairman and Chief Executive Officer, Kurzweil Technologies, Inc.
  • Non-employee Director
  • Member, Scientific Committee
Ray Kurzweil

Mr. Kurzweil is an inventor, entrepreneur and author, and has created several important technologies in the artificial intelligence field. He has received the National Medal of Technology, the MIT-Lemelson Prize, nineteen honorary doctorates and honors from three U.S. Presidents. Mr. Kurzweil was selected as a 2002 inductee into the National Inventors Hall of Fame. Since 1995, Mr. Kurzweil has served as the Chief Executive Officer of Kurzweil Technologies, Inc., a technology development firm. Since January 2013, he has also served as Director of Engineering for Google Inc. He has served as a United Therapeutics director since 2002.

Christopher Patusky, J.D., M.G.A.

  • Principal, Patusky Associates, LLC
  • Former Director, Office of Real Estate - Maryland Department of Transportation
  • Vice Chairman
  • Lead Director
  • Chairman, Nominating and Governance Committee
  • Member, Audit Committee
Christopher Patusky, J.D., M.G.A.

From August 2007 until July 2011, Professor Patusky served as Director, Office of Real Estate, for the Maryland Department of Transportation, where he was responsible for overseeing the Department’s real estate matters statewide, including its transit-oriented development program. He continues to provide part-time services to the Maryland Department of Transportation while offering consulting services to other clients as the founding principal of Patusky Associates, LLC. From 2002 until May 2007, Professor Patusky served as the Executive Director and a member of the faculty of the Fels Institute of Government at the University of Pennsylvania. From 1989 until 2000, Professor Patusky practiced law, focusing on litigation, intellectual property law and business startups. Our Board of Directors has determined that Professor Patusky meets the financial sophistication requirements of NASDAQ’s listing standards. He has served as a United Therapeutics director since 2002.

Louis Sullivan, M.D.

  • Founding President and President Emeritus, Morehouse School of Medicine
  • Former Secretary, United States Department of Health and Human Services
  • Independent Director
  • Member, Compensation Committee
  • Member, Nominating and Governance Committee
  • Member, Scientific Committee
Louis Sullivan, M.D.

Dr. Sullivan currently serves as a Director of Henry Schein, Inc. (since 2001), BioSante Pharmaceuticals, Inc. (since 1994), and Emergent BioSolutions, Inc. (since 2005), all publicly traded companies. Dr. Sullivan was the founding President of Morehouse School of Medicine, from 1981 to 1989 and 1993 to 2002, and he became President Emeritus of Morehouse School of Medicine in July 2002. Dr. Sullivan was also founder and Chairman of Medical Education for South African Blacks, Inc., a member of the National Executive Council for the Boy Scouts of America, and a member of the Board of Trustees of Little League of America. Dr. Sullivan served as Secretary of the United States Department of Health and Human Services from 1989 to 1993. He is a physician certified in internal medicine with a subspecialty certification in hematology. He has served as a United Therapeutics director since 2002.

Tommy G. Thompson, J.D.

  • Former Partner, Akin Gump Strauss Hauer & Feld LLP
  • Former Governor of Wisconsin
  • Former Secretary of Health and Human Services
  • Independent Director
  • Member, Audit Committee
Tommy G. Thompson, J.D.

Before entering the private sector in 2005, Governor Thompson enjoyed a long and distinguished career in public service. As Secretary of Health and Human Services from 2001 to 2005, he was a leading advocate for the health and welfare of all Americans. He also served four terms as Governor of Wisconsin from 1987 to 2001. From 2005 until January 2012, Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP in Washington, D.C. From 2005 to 2009, he also served as the Independent Chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health related challenges. He also served as chairman of the board of directors of AGA Medical Holdings, Inc. from 2005 until November 2010, and is a member of the boards of directors of Centene Corporation, C.R. Bard, Inc., Cytori Therapeutics, Inc., Physicians Realty Trust and TherapeuticsMD, Inc. He previously served on the boards of directors of SpectraScience and CNS Response, Inc. (through December 2009), CareView Communications, Inc. (through January 2014), Cancer Genetics Inc. (through January 2014), and X Shares Advisors (through March 2007). Our Board of Directors has determined that Governor Thompson meets the financial sophistication requirements of NASDAQ’s listing standards. Governor Thompson has served as a United Therapeutics director since 2010.

Employee Directors

Martine Rothblatt, Ph.D., J.D., M.B.A. - Chairman

Roger Jeffs, Ph.D.